C4 Therapeutics (CCCC) Insider Stephen Fawell Buys 62,000 Shares

Stephen Fawell recently purchased 62,000 shares of CCCC on June 24, 2026. This transaction is part of a broader pattern of insider buying at the company, which has seen multiple executives acquiring shares.

Insider Buying and Selling at C4 Therapeutics, Inc.

In addition to Stephen Fawell, insiders such as Laura Bessen and Donna Roy Grogan also bought 62,000 shares each on the same day. Kenneth Carl Anderson made several transactions, including buying 1,070 shares at $2.11 on June 1, 2026, and 4,259 shares at $2.70 on April 1, 2026.

Other Institutional Activity in CCCC

Morgan Stanley increased its holdings in CCCC by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. RA Capital Management, L.P. maintained its position with 8,000,000 shares worth about $21.04 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at $10.16 million.

C4 Therapeutics, Inc. Stock Up 29.8%

Shares of CCCC traded near $4.40 on Saturday. Analysts have maintained a positive outlook on the stock, with Evercore ISI Group keeping a buy rating and a price target of $12 as of June 1, 2026. CCCC's stock has been the subject of several bullish analyst reports, with price targets reaching as high as $30.

Analysts Set New Price Targets

On June 1, 2026, Evercore ISI Group maintained its buy rating on CCCC, setting a price target of $12. Barclays has also reiterated its buy stance with varying targets, including $7 and $5 in recent months. Brookline Capital set a notably high target of $30, reflecting strong confidence in the stock's potential.

Bottom Line

Stephen Fawell's recent purchase of CCCC shares is part of a series of insider buy actions, suggesting confidence in the company. Institutional investors have shown mixed activity, with some increasing and others maintaining their stakes. Analysts remain bullish, with several maintaining buy ratings and setting ambitious price targets. This insider and institutional activity, combined with positive analyst sentiment, highlights the market's interest in CCCC.